All In Biotech

Drug Trial Radar · NCT07644832

An Open-label, Multicenter Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetic/Pharmacodynamic (PK/PD) Characteristics of SR604 Injection in Patients With Hemophilia A/B and Congenital Factor VII Deficiency

Last checked: Nov 19, 2026Latest source record: Jun 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

76

Planned (sponsor's estimate)

Start

May 31, 2024

Primary completion

Dec 31, 2026

Study completion Dec 31, 2026

Sponsor

Sponsor type
Industry
First posted
Jun 12, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety, tolerability, immunogenicity , PK, and PD of a single dose of SR604 in participants with Hemophilia A or Hemophilia B, with or without inhibitors (Part A)and to evaluate the safety, PK, PD, and efficacy of multiple doses of SR604 in participants with Hemophilia A or Hemophilia B, or Factor VII (FVII) deficiency, with or without inhibitors (Part B and Part C).

Conditions

  • Hemophilia A
  • Hemophilia B
  • Factor VII Deficiency

Interventions

  • SR604Drug

    SR604 will be administered as SC injection

  • SR604Drug

    SR604 will be administered as SC injection.

  • SR604Drug

    SR604 will be administered as SC injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A: Incidence of AEs/SAEs/AESITime frame: Part A: From Baseline (Day 1) up to Day 85
  2. PartA: Incidence of drug-related AEs/SAEs/AESIsTime frame: Part A: From Baseline (Day 1) up to Day 85
  3. Part A: Number and incidence of patients with anti-drug antibodies (ADA) and neutralizing antibodiesTime frame: Part A: From Baseline (Day 1) up to Day 85
  4. Part B/ Part C:Treated total annualized bleeding rate (ABR)Time frame: Part B: From Baseline (Day 1) up to Day 211;Part C: From baseline (Day 1) up to Day 393

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • Xiangya Hospital of Central South University

    Changsha, China · Recruiting

  • The First Affiliated Hospital of University of Science and Technology of China

    Hefei, China · Recruiting

  • Jinan Central Hospital

    Jinan, China · Recruiting

  • The First Hospital of Lanzhou University

    Lanzhou, China · Recruiting

  • Ruijin Hospital Shanghai Jiaotong University School of Medicine

    Shanghai, China · Completed

  • The Second Hospital of Shanxi Medical University

    Taiyuan, China · Recruiting

  • Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences

    Tianjin, China · Completed

  • Xian Central Hospital

    Xi'an, China · Recruiting

  • Zhengzhou People's Hospital

    Zhengzhou, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.